Skip to main content
  1. Home
  2. Emerging Tech
  3. Photography
  4. Smart Home
  5. News

There is now a flying surveillance drone for … your home

Add as a preferred source on Google

When it comes to keeping an eye on your home, both while you’re there and while you’re away, there are a handful of options to choose from. You can go with hardwired surveillance cameras, Wi-Fi surveillance cameras, or some other similar options.

Soon though, you might be able to take an even more proactive approach. Meet Cardinal, the world’s first autonomous surveillance drone designed for home use. Developed by Cardinal Robotics, the Cardinal drone is an entirely new way of keeping tabs on your home via an eye in the sky.

Recommended Videos

Inside the the lightweight drone is a 14-megapixel camera capable of shooting full 1080p video. These images remain smooth thanks to its three-axis stabilization technology, and the device is nighttime compatible with a near infrared camera and onboard array of infrared LED lights.

Besides the base specs, not many details have been provided. According to the Cardinal website, the drone has a flight time of 20 minutes and is capable of completing an entire sweep of your home in just two minutes, but no battery information has been given to substantiate the claims.

Furthermore, other than a few renderings and a little copy, there’s not much to go from, which could be a little concerning for those looking to pre-order the device.

Besides the ambiguous details on the battery life and no mention of how the device will automatically recharge itself, another aspect that stands out is the lack of any details of weatherproofing. If you’re paying $4,000 to have a drone keep an eye on your home, it would only make sense it would be able to fly in light rain and know when to stay put in more dangerous weather.

For the time being, Cardinal Robotics is taking pre-orders for the device at $4,000. According to the pricing page, the drone will retail for $6,000 when it hits the market.

The concept looks promising, but we’d need more information before we could assess whether the device will be able to deliver on its promises.

[amz_nsa_keyword keyword=”surveillance drone”]
Gannon Burgett
Former Editor
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more